



Myosin light chain 9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to Yes-associated protein 1 and regulating Hippo signaling

Min Feng, Ningfei Dong, Xin Zhou, Lihong Ma & Rui Xiang

To cite this article: Min Feng, Ningfei Dong, Xin Zhou, Lihong Ma & Rui Xiang (2022) Myosin light chain 9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to Yes-associated protein 1 and regulating Hippo signaling, *Bioengineered*, 13:1, 96-106, DOI: [10.1080/21655979.2021.2008641](https://doi.org/10.1080/21655979.2021.2008641)

To link to this article: <https://doi.org/10.1080/21655979.2021.2008641>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 03 Jan 2022.



Submit your article to this journal [↗](#)



Article views: 76



View related articles [↗](#)



View Crossmark data [↗](#)

RESEARCH PAPER



Myosin light chain 9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to Yes-associated protein 1 and regulating Hippo signaling

Min Feng^a, Ningfei Dong^a, Xin Zhou^a, Lihong Ma^b, and Rui Xiang^b

^aDepartment of Gastroenterology, East Hospital of Zibo Central Hospital, Shandong Province, Zibo City, China; ^bDepartment of Gastroenterology, West Hospital of Zibo Central Hospital, Zibo, Shandong Province, China

ABSTRACT

Colorectal cancer is a common type of cancer with high incidence and poor prognosis. Increased expression of myosin light chain 9 (MYL9) has been reported in early-stage and recurrent colorectal cancer tissues. This study aimed to investigate the precise role of MYL9 on the progression of colorectal cancer. MYL9 expression in several colorectal cancer cell lines was detected by Western blotting and RT-qPCR. Following MYL9 overexpression or knockdown, MYL9 expression was determined via RT-qPCR. Cell proliferation was detected with Cell Counting Kit-8 assay. Cell invasion, migration and angiogenesis were, respectively, examined with transwell, wound healing and tube formation assays. The binding between MYL9 and Yes-associated protein 1 (YAP1) was verified by a co-immunoprecipitation assay. The expression of YAP1, connective tissue growth factor and cysteine-rich angiogenic inducer 61 was examined by Western blotting. Subsequently, YAP1 silencing or Hippo antagonist was performed to clarify the regulatory mechanisms of MYL9 in colorectal cancer progression. Experimental results showed that MYL9 expression was elevated in colorectal cancer cell lines. MYL9 overexpression promoted cell proliferation, invasion, migration and angiogenesis, while silencing of MYL9 exerted the opposite effects. Results of co-immunoprecipitation assay indicated that MYL9 could bind to YAP1. Further experiments revealed that MYL9 affected the expression of YAP1 and its downstream signaling proteins. Afterward, YAP1 knockdown or the addition of Hippo antagonist inhibited the proliferation, invasion, migration and angiogenesis of colorectal cancer cells. Overall, MYL9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to YAP1 and thereby activating Hippo signaling.

ARTICLE HISTORY

Received 14 October 2021
Revised 15 November 2021
Accepted 16 November 2021

KEYWORDS

MYL9; YAP1; Hippo; colorectal cancer; migration; invasion

Introduction

Colorectal cancer ranks third among all common cancers worldwide, and the number of deaths increases annually with age [1]. Colorectal cancer is more prevalent in Western countries, and its incidence is lower in women than in men. Although incidence rates are beginning to decline in highly developed countries due to the availability of screening programs and colonoscopies [2], the incidence rates of colorectal cancer in developing countries are not encouraging due to the high cost of screening and surgery [3]. Furthermore, there has been a significant increase in the rates of colorectal cancer in patients aged <50 years [4]. Despite the fact that genetics, lifestyle, obesity and environmental factors may be associated with the incidence of

colorectal cancer, the exact reasons for the increased number of cases are not fully understood [5].

Myosin light chain 9 (MYL9) is the most extensively studied member of the myosin superfamily. MYL9 protein expression increases significantly with tumor recurrence [6]. However, the expression of MYL9 in cancer cells is controversial. MYL9 expression was shown to be higher in esophageal squamous cell carcinoma [7] but lower in prostate cancer [8] and non-small cell lung cancer [9]. Additionally, it has been suggested that MYL9 expression is increased in early-stage [10] and recurrent colorectal cancer tissues [11]. However, the specific role and regulatory mechanisms of MYL9 in colorectal cancer have not been extensively investigated.

CONTACT Rui Xiang  xiangrui76@163.com  Department of Gastroenterology, West Hospital of Zibo Central Hospital, No. 10 Shanghai Road, Zhangdian District, Zibo City, Shandong Province 255000, China

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

On the other hand, on the basis of database the BioGRID database (<https://thebiogrid.org/>), MYL9 can combine with Yes-associated protein 1 (YAP1). YAP1 signaling is a pro-cancer signaling pathway involved in the role of colorectal cancer [12]. YAP1 promotes cancer development in a variety of ways, including promoting a malignant phenotype, expansion of cancer stem cells, and cancer cell resistance [13]. Thus, pharmacological or genetic inhibition of YAP1 can inhibit tumor progression. Numerous studies have demonstrated that YAP1 plays an important role in the development of colorectal cancer, promoting the proliferation and survival of colorectal cancer cells [14]. YAP1 is one of the most important regulators in the Hippo pathway, which is a novel tumor suppressor pathway [15]. The Hippo signaling pathway acts as a key player in the regulation of cell proliferation, migration and organ growth [13].

In the current study, the expression of MYL9 in several colorectal cancer cell lines was detected. Then, MYL9 was silenced or overexpressed to explore whether MYL9 affects the biological behavior of colorectal cancer cells. The latent regulatory mechanism of MYL9 related to AP1-Hippo signaling in HCC progression is explored.

Materials and methods

Cell culture and treatment

Human normal intestinal epithelium cells (NCM460) and several colorectal cancer cell lines (SW480, SW620, HT-29, HCT116) were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were grown in Dulbecco's modified Eagle medium (DMEM; Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Rwdls, Shenzhen, China) and 100 U/mL penicillin, and 100 mg/mL streptomycin in a humidified atmosphere of 5% CO₂ at 37°C. The human umbilical vein endothelial cells (HUVECs) were maintained in the Vascular Cell Basal Medium (ATCC, Manassas, VA, USA) containing with Vascular Endothelial Cell Growth Kit-VEGF (Abebio, Wuhan, China) at 37°C in a suitable incubator. Hippo inhibitor (CA3) dissolved in dimethylsulfoxide was purchased from

SelleckChem and diluted to 1 µM with phosphate buffer saline (PBS) before use [16,17]. HCT116 cells were treated with 1 µM hippo inhibitor for 1 h before transfection.

Cell transfection

Specific small interfering RNA (siRNA) and negative control siRNAs were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). SiRNAs against MYL9, namely si-MYL9-1 and si-MYL9-2, as well as siRNA-YAP1-1 and siRNA-YAP1-2 were transfected into HCT116 cells by using Lipofectamine 3000 transfection reagent (Invitrogen, Thermo Fisher Scientific, Inc.) following the recommendations of manufacturer. A plasmid encoding MYL9 (Shanghai GenePharma Co., Ltd.) was designed to overexpress MYL9. The successful transfection was evaluated via reverse transcription-quantitative PCR (RT-qPCR) and Western blot assays at 48 h after transfection.

Cell proliferation assay

Cell proliferation was determined by Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan). HCT116 cells (1×10^3 cells/well) were seeded in 96-well plates for the incubation of 24, 48, 72 h under the conditions of 37°C and 5% CO₂. Subsequently, 10 µL CCK-8 solution was added into medium. Cell proliferation was estimated with a microplate reader (Reagen, Shenzhen, China) at absorbance of 450 nm.

RT-qPCR assay

RT-qPCR was used in the detection of mRNA expression of the MYL9 and YAP1 genes. RNA extraction was carried out in HCT116 cell lines using Eastep® Super Total RNA Extraction Kit (Promega Corporation). Experimental steps were performed strictly as instructed by the reagent manufacturer. RNA transcription was reverse transcribed to complementary DNA (cDNA) using an RT kit (Takara, Biotechnology Co., Ltd.). The concentration and purity of RNA were determined by using a BioPhotometer (Eppendorf, Hamburg, Germany). Afterward, PCR assays were

performed with SYBR Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on an ABI 7300 thermal-recycler (Applied Biosystems; Thermo Fisher Scientific, Inc.). Gene expression was calculated as fold change according to the $2^{-\Delta\Delta C_q}$ method [18]. The glyceraldehyde-phosphate dehydrogenase (GAPDH) was used as an endogenous control for normalization.

Western blotting

Cell lysis buffer was used to cleave proteins on ice for 30 min. Then, the lysed cells were processed by centrifugation for 10 min and the supernatant was collected and protein quantification was performed by means of a bicinchoninic acid (BCA) Protein assay kit (GlpBio, Montclair, USA) following the standard procedures of the manufacturer. Total protein (50 μ g per lane) was separated with the help of 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel electrophoresis and then transferred to polyvinylidene fluoride (PVDF) membranes (Roche, Basel, Switzerland), which were later washed with PBS three times and blocked with 5% skimmed milk. For the next step, the membranes were incubated with diluted antibody overnight at 4°C. After three series of washing at room temperature, the corresponding secondary antibodies were added for 1 h incubation. Finally, visualization was performed with the enhanced chemiluminescent substrate (Yeasen, Shanghai, China) solution. ImageJ software (National Institutes of Health) was used to evaluate the band density. The relative protein expression was calculated using GAPDH as the loading control.

Wound healing assay

Cells were plated into 6-well plates. Once the cells reached 95% confluence, a pipette tip was utilized to scratch the cell monolayers. The original medium was discarded and replaced with a serum-free medium. Cell images were taken by an inverted microscope (Olympus, Tokyo, Japan) 48 h after transfection.

Cell invasion assay

Transwell assay was carried out to test the cell invasion capacity after cell transfection for 48 h.

Briefly, Matrigel was diluted and smeared on the upper chamber side of the membrane at the bottom of the chambers and placed at 37°C for 30 minutes to polymerize into a gel. Then, cell suspensions were prepared and added to the chambers. The lower chamber was filled with the medium containing 10% FBS. Subsequently, the chambers were removed and the culture medium was discarded, washed twice with calcium-free PBS. Cells were fixed with methanol for 30 minutes and then stained with 0.1% crystal violet for 20 min. The non-invading cells on the upper surface of the filter were gently wiped off with cotton swabs, followed by washing, and the invading cells were finally counted under a microscope (Olympus, Tokyo, Japan).

Tube formation assay

The angiogenic capacity of tumor cells was determined by a tube formation assay. Pre-chilled Matrigel was applied to 24-well plates and incubated for 45 min at 37°C. The prepared suspension of HUVECs was added to each well coated with gel and treated differently in the culture medium. Finally, after 24 h incubation, the formation of endothelial tubes was observed and photographed under a microscope (Olympus, Tokyo, Japan).

Co-immunoprecipitation (Co-IP) detection

Co-IP was performed to determine the binding of proteins in HCT116 cells. The treated supernatant was collected and added to the corresponding antibody for 1 h at 4°C with shaking. Add Protein A-Sepharose suspension was added by shaking at 4°C for 30 minutes. After washing and collecting, 1X SDS Gum Spiking Buffer and mixture were added into the pellet beads and boiled for 4 minutes. The samples were added to the SDS-PAGE gradient gel for electrophoresis overnight. The protein bands were observed by using Komasa Brilliant Blue staining. Subsequently, the sections were washed twice with 1 ml 50% acetonitrile for 3 min and the proteins in the gel were digested with trypsin. The peptides were separated by narrow-well high-performance liquid chromatography (Agilent Technologies, Santa Clara, CA, USA). The collected peptides were subjected to

automated Edman degradation sequencing on an ABI 477A (Thermo Fisher Scientific, Waltham, MA, USA).

Statistical analysis

Values are presented as the mean $\pm$ standard deviation and analysis was performed using GraphPad Prism 8.0 (GraphPad Software, Inc.). Differences among groups were evaluated by one-way analysis of variance (ANOVA) with Tukey's post hoc test. A level of $p < 0.05$ was considered significant.

Results

MYL9 expression is increased in colorectal cancer cell lines

Compelling evidence indicates that MYL9 protein expression increases significantly with tumor recurrence and MYL9 level is elevated in early-stage and recurrent colorectal cancer tissues [10,11]. To explore the precise role of MYL9 on the progression of colorectal cancer, the expression of MYL9 in several human colorectal cancer cell lines was measured via Western blotting and RT-qPCR. As presented in Figure 1a and b, MYL9 protein and mRNA expression was upregulated in colorectal cancer cell lines SW480, SW620, HT-29 and HCT116, compared with the NCM460 cells. HCT116 cells were subsequent assays as MYL9 expression was highest in this cell line. These results indicate the abnormally high expression of MYL9 in colorectal cancer cells.

MYL9 regulates proliferation, migration, invasion and angiogenesis of colorectal cancer cells after overexpression or knockdown of MYL9

To verify the influence of MYL9 on the progression of colorectal cancer, MYL9 was silenced or overexpressed by transfection with siRNA-MYL9 or Ov-MYL9 in HCT116 cells. There was a notable down-regulation in the expression of MYL9 compared with the siRNA group after MYL9 knocked down (Figure 2a). SiRNA-MYL9-1 was chosen for the next experiments on account of its stronger level of interference. As presented in Figure 2b, MYL9 expression was rapidly increased after transfection with Ov-MYL9, as compared with the empty vector control group. Additionally, it can be easily observed in Figure 2c that proliferation of HCT116 cells was remarkably decreased following transfection with siRNA-MYL9-1 compared with the siRNA-NC group, while a dramatic rise was found after MYL9 overexpression when compared with the Ov-NC group. As presented in Figure 2d-G, cell migration and invasion were decreased following transfection with siRNA-MYL9-1, but there was a notable increase in both following MYL9 overexpression. Additionally, results of Figure 2h reveals that there was a marked decrease in the protein levels of matrix metalloproteinase (MMP)2 and MMP9 following MYL9 knockdown, while there was a notable increase in the expression of MMP2 and MMP9 protein levels following MYL9 overexpression. These findings suggested that MYL9 silencing inhibits the proliferation, migration and invasion of HCT116 cells while MYL9 overexpression promotes the proliferation, migration and invasion of HCT116 cells.




Figure 1. MYL9 expression was elevated in colorectal cancer cell lines. (a-b) Detection of MYL9 protein and mRNA expression in several colorectal cancer cell lines (SW480, SW620, HT-29 and HCT116) and human normal intestinal epithelium cells (NCM460) using Western blotting and RT-qPCR. *** $P < 0.001$ vs. NCM460.




Figure 2. MYL9 affected cell proliferation, migration and invasion of colorectal cancer cells after overexpression or knockdown of MYL9. (a) Detection of MYL9 mRNA expression after transfection with siRNA-MYL9-1 or siRNA-MYL9-2 in HCT116 cells by RT-qPCR assay. *** $P < 0.001$ vs. siRNA-NC. (b) Inspection of overexpression of MYL9 in colorectal cancer cell lines was carried out by RT-qPCR. *** $P < 0.001$ vs. Ov-NC. (c) CCK-8 was adopted to detect cell proliferation levels. (d-e) Wound healing was used to evaluate the ability of cell migration. (f-g) Transwell assay was performed for cell invasion. (h). Western blot assay was used to test the expression of MMP2 and MMP9. ** $P < 0.01$, *** $P < 0.001$ vs. siRNA-NC; ### $P < 0.001$ vs. Ov-NC.

MYL9 affects the angiogenesis of colorectal cancer cells after overexpression or knockdown of MYL9

Accumulating study confirms that angiogenesis plays an important role in the development of tumor metastasis, and inhibition of this process can significantly prevent the development and spread of tumor [19,20]. In this study, HUVECs

were added to each group of medium to verify the angiogenic ability by means of a tube formation assay. The tubule formation capacity of siRNA-MYL9 was diminished compared to siRNA-NC but increased in Ov-MYL9 compared to Ov-NC (Figure 3). We suggest that expression of MYL9 is positively correlated with the angiogenic ability of colorectal cancer cells.




Figure 3. MYL9 affects the angiogenesis of colorectal cancer cells after overexpression or knockdown of MYL9. Tube formation assay was utilized to detect in vitro angiogenic capacity. * $P < 0.05$ vs. siRNA-NC; ### $P < 0.001$ vs. Ov-NC.

MYL9 can interact with YAP1 and regulate the expression of YAP1 and its downstream signaling proteins after overexpression or knockdown of MYL9

To explore the potential mechanisms of MYL9 on the regulation of colorectal cancer progression, BioGRID database (<https://thebiogrid.org/>) was used to predict the genes that could interact with MYL9. It was found that YAP1 could bind to MYL9 (Figure 4a). To explore the relationship between MYL9 and YAP1, as well as the impact of MYL9 on YAP1, the binding between MYL9 and YAP1 was verified by Co-IP experiment in HCT116 cells. The experiments demonstrated that MYL9 and YAP1 could bind to each other (Figure 4b). However, this is in vitro (Co-IP), and only in cells not in actual tissues and therefore we only demonstrated here a putative interaction between the two proteins. Additionally, the levels of YAP1 and its downstream signaling protein connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61) were distinctly reduced following transfection with siRNA-MYL9-1, but were enhanced following the overexpression of MYL9 (Figure 4c). Taken together, MYL9 is demonstrated to bind to YAP1, and MYL9 silencing represses the expression of YAP1 and its downstream signaling proteins, which are promoted by MYL9 overexpression.

MYL9 promotes the proliferation, migration and invasion of colorectal cancer cells via YAP1-Hippo signaling

To further investigate whether MYL9 affected colorectal cancer cells through YAP1-Hippo

signaling, siRNA-YAP1-1 and siRNA-YAP1-2 were transfected into HCT116 cells and 1 μ M Hippo inhibitor was added to the culture medium. It was observed that YAP1 expression showed a notably downregulation after transfection with siRNA-YAP1-1 or siRNA-YAP1-2 (Figure 5a-b). SiRNA-YAP1-1 was chosen for the subsequent experiment due to the lower YAP1 expression. As displayed in Figure 5c, it was shown that MYL9 overexpression promoted cell proliferation. Following MYL9 overexpression and YAP1 knockdown, cell proliferation was greatly reduced. Similar results were obtained treating the cells with a Hippo inhibitor instead of siRNA-YAP1-1. Subsequently, it was apparent in Figure 5d-g that under the overexpression of MYL9 and YAP1 knockdown, the migratory and invasive abilities of HCT116 cells were markedly reduced compared with the Ov-MYL9+ siRNA-NC group. Similarly, as comparison to the Ov-MYL9 group, a same decreased trend was observed in the group of MYL9 overexpression and Hippo inhibitor. In addition, there was also an obvious reduction in the protein levels of MMP2 and MMP9 in both the Ov-MYL9+ siRNA-YAP1 and Ov-MYL9+ Hippo inhibitor groups (Figure 5h). In general, these results demonstrate that MYL9 promotes the proliferation, migration and invasion of colorectal cancer cells through YAP1-Hippo signaling.

MYL9 promoted the angiogenesis of colorectal cancer cells via YAP1-Hippo signaling

To determine whether MYL9 affected colorectal carcinogenesis through YAP1-Hippo signaling, angiogenesis was assessed experimentally.




Figure 4. MYL9 bound to YAP1 and regulated the expression of YAP1 and its downstream signaling proteins after overexpression and knockdown of MYL9. (a) BioGRID database (<https://thebiogrid.org/>) was used to predict that MYL9 could interact with YAP1. (b) Co-IP assay was used to validate the binding between MYL9 and YAP1 in HCT116 cells. (c) Expression of YAP1 and its downstream signaling proteins CTGF and CYR61 was examined by Western blotting. *** $P < 0.001$ vs. siRNA-NC; ## $P < 0.01$, ### $P < 0.001$ vs. Ov-NC.

According to the results presented in Figure 6, YAP1 deletion notably reversed the impact of MYL9 overexpression on the tube formation capacity. Consistently, the addition of Hippo inhibitor also remarkably decreased the ability of tube formation in HUVECs when compared with the Ov-MYL9 group. These results suggest that MYL9 contributes to the angiogenesis of colorectal cancer cells through YAP1-Hippo signaling.

Discussion

Colorectal cancer remains one of the cancers that seriously threaten human health, with poor prognosis and high recurrence rates as obstacles to its successful treatment [21,22]. Further research is

needed to determine treatment goals. In the current study, MYL9, a pivotal gene associated with recurrence in colorectal cancer patients, was selected to determine its role in colorectal cancer. This study confirmed that MYL9 was highly expressed several colorectal cancer cell lines and MYL9 silencing inhibited cell proliferation, invasion, migration and angiogenesis, while MYL9 overexpression promoted cell proliferation, invasion, migration and angiogenesis. Besides, it was also demonstrated that MYL9 could bind to YAP1, and MYL9 could regulate the expression of YAP1 and its downstream signaling proteins CTGF and CYR61. Mechanically, MYL9 promoted the proliferation, invasion, migration and angiogenesis of colorectal cancer cells via YAP1-Hippo signaling.




Figure 5. MYL9 promoted proliferation, migration and invasion of colorectal cancer cells through YAP1-Hippo signaling. (a-b) Western blotting and RT-qPCR were adopted to test the expression level of YAP1 protein and mRNA in after YAP1 silencing. *** $P < 0.001$ vs. siRNA-NC. (c) CCK-8 assay was utilized to detect cell proliferation. (d-e) Wound healing was used to evaluate the ability of cell migration. (f-g) Transwell assay was performed for the evaluation of cell invasion. (h). Western blot assay was used to test the expression of MMP2 and MMP9. *** $P < 0.001$ vs. control; # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$ vs. Ov-MYL9+ siRNA-NC; $\Delta P < 0.05$, $\Delta\Delta P < 0.01$, $\Delta\Delta\Delta P < 0.001$ vs. Ov-MYL9.

MYL9 is one of the fibroblast-specific biomarkers of poor prognosis in colorectal cancer [23]. The increased expression of MYL9 in early-stage colorectal cancer tissues and recurrent colorectal cancer tissues has been mentioned previously [10,11]. In this study, it was found that MYL9 expression was notably elevated in several human colorectal cancer cell lines. An increasing number of researches have

validated that MYL9 can play a role in the proliferation, metastasis and invasion of cancer cells. For example, it has been shown that MYL9 mediates the proliferation, migration and invasion of colon cancer tumor stem cells by interacting with sponge microRNA-412-3p and long-stranded non-coding RNA MBNL1-AS1 [24]. Furthermore, miR-663a promotes proliferation and migration of




Figure 6. MYL9 promoted angiogenesis in colorectal cancer cells via YAP1-Hippo signaling. Tube formation assay was implemented to detect in vitro angiogenesis. *** $P < 0.001$ vs. control; ### $P < 0.001$ vs. Ov-MYL9+ siRNA-NC; ΔΔΔ $P < 0.001$ vs. Ov-MYL9.

osteosarcoma by targeting MYL9 [25]. Overexpression of myocardin-related transcription factor A significantly promotes the migration of breast cancer cells through reverse transcription of MYL9 and CYR61 genes [26]. In this study, MYL9 silencing was followed by reduced cell proliferation, migration and invasion, whereas MYL9 overexpression exerted the opposite effects on these process. Previous evidence has indicated that MMP2 and MMP9 are two important genes that are closely related to the migration of tumor cells, including colorectal cancer [27–29]. The present study revealed that MYL9 deletion downregulated the expression of MMP2 and MMP9 while MYL9 overexpression upregulated the expression of MMP2 and MMP9 in colorectal cancer cells. Moreover, angiogenesis plays an important role in the development of tumor metastasis, and inhibition of this process can significantly prevent the development and spread of tumor [19,20]. MYL9 is critical in the process of sprouting angiogenesis [30]. Results of the current study indicated that MYL9 knockdown attenuated the tubule formation capacity of HCT116 cells, suggesting the potential pro-angiogenic role of MYL9 in colorectal cancer.

Based on the BioGRID database, it was demonstrated that MYL9 could bind to YAP1, which is a pro-cancer signaling pathway involved in colorectal cancer. Cyr61 and CTGF are two downstream signaling proteins of YAP1 that belong to the CCN family and are involved in cell proliferation, differentiation and apoptosis [31]. It was confirmed by in vitro Co-IP and Western blotting assays that MYL9 can bind

YAP1 to activate or repress its expression and that of downstream genes CYR61 and CTGF. It has been well reported that YAP1 is a transcriptional coactivator of the Hippo pathway that plays an oncogenic role in a variety of malignancies [32–34]. Dysregulation of the Hippo pathway may induce tumor development, including colorectal, lung, liver and gastric cancers [35,36]. In our experiments, MYL9 was found to promote proliferation, invasion, migration, angiogenesis in colorectal cancer cells via binding to YAP1 and regulating Hippo signaling.

Conclusion

In conclusion, this study elucidated that MYL9 potentially regulated cell proliferation, migration, invasion and angiogenesis in colorectal cancer by interacting with YAP1 and regulating Hippo signaling. This work on MYL9 identified its novel effects in colorectal cancer. Later efforts will be concentrated on determining the mechanism of this effect, potentially giving rise to novel molecules that make use of this property to prevent colorectal cancer.

Availability of data and materials

The analytical data in this study can be obtained from the corresponding author upon reasonable request.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

The authors reported there is no funding associated with the work featured in this article.

References

- [1] Brenner H, Kloor M, Pox CP, et al. Colorectal cancer. *Lancet*. **2014**;383:1490–1502.
- [2] Stock C, Pulte D, et al. Subsite-specific colorectal cancer risk in the colorectal endoscopy era. *Gastrointest Endosc*. **2012**;75:621–630.
- [3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. **2018**;68:394–424.
- [4] Kasi PM, Shahjehan F, Cochuyt JJ, et al. Rising proportion of young individuals with rectal and colon cancer. *Clin Colorectal Cancer*. **2019**;18:e87–e95.
- [5] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. *Lancet*. **2019**;394:1467–1480.
- [6] Kruthika BS, Sugur H, Nandaki K, et al. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma. *J Clin Pathol*. **2019**;72:677–681.
- [7] Wang JH, Zhang L, Huang ST, et al. Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma. *PLoS One*. **2017**;12:e0175280.
- [8] Huang YQ, Han ZD, Liang YX, et al. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer. *Med Oncol*. **2014**;31:820.
- [9] Tan X, Chen M. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data. *Tumour Biol*. **2014**;35:12189–12200.
- [10] Zhao B, Baloch Z, Ma Y, et al. Identification of potential key genes and pathways in early-onset colorectal cancer through bioinformatics analysis. *Cancer Control*. **2019**;26(1):1073274819831260.
- [11] Qiu X, Cheng SH, Xu F, et al. Weighted gene co-expression network analysis identified MYL9 and CNN1 are associated with recurrence in colorectal cancer. *J Cancer*. **2020**;11:2348–2359.
- [12] Lee KW, Lee SS, Kim SB, et al. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. *Clin Cancer Res*. **2015**;21:357–364.
- [13] Shibata M, Ham K, Hoque MO, et al. A time for YAP1: tumorigenesis, immunosuppression and targeted therapy. *Int J Cancer*. **2018**;143:2133–2144.
- [14] Zhou D, Zhang Y, Wu H, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. *Proc Natl Acad Sci U S A*. **2011**;108:E1312–1320.
- [15] Avruch J, Zhou D, Bardeesy N, et al. YAP oncogene overexpression supercharges colon cancer proliferation. *Cell Cycle*. **2012**;11(6):1090–1096.
- [16] Mickle M, Adhikary G, Shrestha S, et al. VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype. *Mol Carcinog*. **2021**;60:497–507.
- [17] Qi L, Shi C, Li J, et al. Yes-associated protein promotes cell migration via activating Wiskott-Aldrich syndrome protein family member 1 in oral squamous cell carcinoma. *J Oral Pathol Med*. **2019**;48:290–298.
- [18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-ΔΔC_T} Method. *Methods*. **2001**;25:402–408.
- [19] Wang R, Ma Y, Zhan S, et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-kappaB pathway to induce VEGFA expression. *Cell Death Dis*. **2020**;11:55.
- [20] Xiaoxia X, Jing S, Dongbin X, et al. Realgar nanoparticles inhibit migration, invasion and metastasis in a mouse model of breast cancer by suppressing matrix metalloproteinases and angiogenesis. *Curr Drug Deliv*. **2020**;17:148–158.
- [21] Du F, Li X, Feng W, et al. SOX13 promotes colorectal cancer metastasis by transactivating SNAIL2 and c-MET. *Oncogene*. **2020**;39:3522–3540.
- [22] Liu Y, Zhao C, Sun J, et al. Overexpression of small nucleolar RNA SNORD1C is associated with unfavorable outcome in colorectal cancer. *Bioengineered*. **2021**;12:8943–8952.
- [23] Zhou Y, Bian S, Zhou X, et al. Single-cell multiomics sequencing reveals prevalent genomic alterations in tumor stromal cells of human colorectal cancer. *Cancer Cell*. **2020**;38:818–828 e815.
- [24] Zhu K, Wang Y, Liu L, et al. Long non-coding RNA MBNL1-AS1 regulates proliferation, migration, and invasion of cancer stem cells in colon cancer by interacting with MYL9 via sponging microRNA-412-3p. *Clin Res Hepatol Gastroenterol*. **2020**;44:101–114.
- [25] Zhao S, Xiong W, Xu K. MiR-663a, regulated by lncRNA GAS5, contributes to osteosarcoma development through targeting MYL9. *Hum Exp Toxicol*. **2020**;39:1607–1618.
- [26] Zhang C, Luo X, Liu L, et al. Myocardin-related transcription factor A is up-regulated by 17beta-estradiol and promotes migration of MCF-7 breast cancer cells via transactivation of MYL9 and CYR61. *Acta Biochim Biophys Sin (Shanghai)*. **2013**;45:921–927.
- [27] Zhang X, Shi G, Gao F, et al. TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLCgamma. *Oncol Rep*. **2019**;41:2117–2125.
- [28] Kalhori V, Tornquist K. MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells. *Mol Cell Endocrinol*. **2015**;404:113–122.

- [29] Liu H, Li A, Sun Z, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by regulating miR-205-5p/VEGFA axis. *Hum Cell.* [2020](#);33:386–396.
- [30] Franco CA, Blanc J, Parlakian A, et al. SRF selectively controls tip cell invasive behavior in angiogenesis. *Development.* [2013](#);140:2321–2333.
- [31] Chu CY, Chang CC, et al. Connective tissue growth factor (CTGF) and cancer progression. *J Biomed Sci.* [2008](#);15:675–685.
- [32] Warren JSA, Xiao Y, Lamar JM. YAP/TAZ activation as a target for treating metastatic cancer. *Cancers (Basel).* [2018](#);10:115.
- [33] Steinhardt AA, Gayyed MF, Klein AP, et al. Expression of Yes-associated protein in common solid tumors. *Hum Pathol.* [2008](#);39:1582–1589.
- [34] Song S, Li Y, Xu Y, et al. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. *Mol Oncol.* [2020](#);14:1410–1426.
- [35] Harvey KF, Zhang X, Thomas DM, et al. The Hippo pathway and human cancer. *Nat Rev Cancer.* [2013](#);13:246–257.
- [36] Wang H, Di X, Bi Y, et al. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p. *Bioengineered.* [2021](#);12:1791–1802.